NRD
ATRC icon

Nebula Research & Development’s AtriCure ATRC Stock Holding History

Nebula Research & Development’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,577
Closed -$244K – 954
2025
Q1 		$244K Sell
7,577
-9,786
-56% -$363K 0.02% 816
2024
Q4 		$531K Sell
17,363
-9,703
-36% -$312K 0.06% 532
2024
Q3 		$759K Sell
27,066
-27,301
-50% -$673K 0.09% 409
2024
Q2 		$1.24M Buy
54,367
+38,788
+249% +$895K 0.2% 156
2024
Q1 		$474K Buy
+15,579
New +$522K 0.1% 371

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Nebula Research & Development's ATRC Position: Q2 2025 in Review

Nebula Research & Development sold out of AtriCure (ATRC) in Q2 2025, closing a stake of 7,577 shares — an estimated $244K sold.

Nebula Research & Development first reported a position in ATRC in Q1 2024 and held it in 5 quarters. The position peaked at $1.24M in Q2 2024. 201 funds tracked by Wall St. Rank hold ATRC as of Q2 2025.

  • Nebula Research & Development reported no remaining AtriCure position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 7,577 AtriCure shares in Q2 2025, an estimated $244K.
  • Nebula Research & Development first reported a position in AtriCure in Q1 2024 and held it in 5 quarters.
  • Nebula Research & Development's AtriCure position peaked at $1.24M in Q2 2024.
  • 201 funds tracked by Wall St. Rank held AtriCure as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.